Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | How machine learning models may play a role in therapy selection for multiple myeloma

Jamin Koo • 27 Sep 2023
IMS 2023
Multiple Myeloma

Jamin Koo, PhD, Stanford University, Stanford, CA, comments on how machine learning models may be used to improve treatment selection in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Cofounder of ImpriMed

More from Jamin Koo

1:05
Using machine learning to predict the outcomes of patients with NDMM being treated with VRd
Jamin Koo • 27 Sep 2023
0:51
Machine learning-based sequential analysis to assist selection between VMP & Rd for NDMM
Jamin Koo • 27 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals